The collapse of the $160 billion mega merger between US pharma giant Pfizer (NYSE: PFE) and Ireland-incorporated Allergan (NYSE: AGN) set the tone for a quiet month for pharmaceutical collaborations and acquisitions, though things livened up as April ended.
Signs of increased activities in recent days have included US biopharma major AbbVie (NYSE: ABBV) acquiring oncology firm Stemcentrx, and the upping of interest from several companies in USA-based Medivation (Nasdaq: MDVN), with French pharma giant Sanofi (Euronext: SAN) having its $9.3 billion takeover bid rejected, though tals are expected to continue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze